Skip to main content

Table 1 Comparison of the baseline data of the two groups before and after PSM

From: Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer

 

Before PSM

 

After PSM

 

Variable

Apatinib group

(n = 44)

Control group (n = 100)

P

Apatinib group

(n = 36)

Control group (n = 72)

P

Age, years (\(\overline{x}\) ± s)

52.48 ± 9.96

51.76 ± 9.42

0.69

52.28 ± 8.32

53.39 ± 8.32

0.515

Histology

  

0.786

  

0.991

 Serous

32

77

 

28

54

 

Endometrioid

4

8

 

3

6

 

 Mucinous

3

9

 

2

6

 

 Clear

1

2

 

1

2

 

 Other

4

4

 

2

4

 

FIGO Stage

  

0.03

  

0.297

 IIIc

24

79

 

23

53

 

 IV

20

21

13

19

 

ECOG performance status

 

0.776

  

0.988

 0

10

20

 

8

16

 

 1

17

45

 

16

33

 

 2

17

35

 

12

23

 

Recurrent lesions

 

0.033

  

0.637

 In the pelvic cavity

11

24

 

10

17

 

Far beyond the pelvis

33

76

 

26

55

 

Basic illness

  

0.592

 

0.779

 

 Yes

17

34

 

13

28

 

 No

27

66

 

23

44